Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective

Table 2 Drug acquisition costs

Drug (brand)	Drug (generic)	Dose (mcg)	Pack size	Pack cost (PTP + VAT)^a [26] Pack cost (PTP + VAT)^a [26]	Dosing	Annual acquisition cost^a
Comparator drug costs
Spiolto Respimat	TIO/OLO	5/5	30 doses (60 pulsations)	€81.49	2 inhalations once daily	€992
Anoro Ellipta	UMEC/VI	62.5/25	30 doses	€70.25	1 inhalation once daily	€855
Subsequent treatment and other drugs costs
Spiriva Handihaler^b	TIO	18	30 doses	€49.06	1 inhalation once daily	€597
Seretide Accuhaler^b	SAL/FP	50/500	60 doses	€41.28	1 inhalation twice daily	€503
Flixotide Accuhaler^c	FP	500	60 doses	€31.47	2 inhalations once daily	€383
Ventolin^d	Salbutamol	100	200 doses	€2.69	Based on head-to-head study [25]Based on head-to-head study [25]

^aSource: Pack cost is taken from the Ministerio de Sanidad, Servicios Sociales e Igualdad. Available at: https://www.msssi.gob.es/en/home.htm Accessed February 2018
^bTIO + SAL/FP administered together as escalation treatment for both UMEC/VI and TIO/OLO arm in base case
^cadded on to UMEC/VI in an escalation strategy tested in a sensitivity analysis
^drescue medication, modeled based on data from the head-to-head study [25]: 1.77 dose inhalations per day for TIO/OLO, 1.51 dose inhalations per day for UMEC/VI
FP fluticasone propionate, PTP price to public, SAL salmeterol xinafoate, TIO/OLO tiotropium/olodaterol, UMEC/VI umeclidinium/vilanterol, VAT value added tax

ISSN: 1465-993X